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There is now evidence that adjuvant therapy is useful in breast
carcinomas without axillary lymph-node metastases (Mansour et
al, 1989; Fisher et al, 1996). Various histological features have
been proposed as prognostic factors (Davis et al, 1986; van de
Velde et al, 1986; Lee et al, 1990; Clayton et al, 1991; Clemente et
al, 1992; Gasparini et al, 1994; Kato et al, 1996; O’Malley et al,
1996), but no indicators for the need of adjuvant treatment have
yet been clearly established. Some studies have suggested that
peritumour lymphatic and blood vessel invasion (PLBI) (Lee et al,
1990; de Mascarel et al, 1998; Lampe et al, 1998) or peritumour
lymphatic vessel invasion (LVI) (Clemente et al, 1992; Gasparini
et al, 1994; Lauria et al, 1996) are significant prognostic factors.
However, there are few studies of the prognostic significance of
peritumour blood vessel invasion (BVI) (Gasparini et al, 1994;
Kato et al, 1996). It was more difficult to identify invasion of small
vessels and capillaries and the larger vessels surrounded by elastic
tissue in breast cancer in routine haematoxylin and eosin (H&E)-
stained tissue sections than in gastric or colorectal cancer. A wide
range of frequencies has been reported for BVI among patients
with breast cancer. The differences may be due to various
methods, interobserver discordance, and the characteristics of
different series, but the prognostic significance of BVI remains
controversial (Sears et al, 1982; Weigand et al, 1982; van de Velde
et al, 1986; Lauria et al, 1996).
This study was undertaken to determine the absolute and 
relative value of BVI using both factor VIII-related antigen and
elastica van Gieson staining, p53, PCNA, c-erbB-2 which are 
relatively new prognostic factors, and conventional prognostic
factors in predicting relapse-free survival (RFS) and overall
survival (OS) rates with long-term follow-up in Japanese patients
with node-negative breast cancer.
PATIENTS AND METHODS
Patients
Data for this study were collected from 200 selected node-negative
breast cancer patients operated on between 1971 and 1987 at the
Tokyo Women’s Medical University Hospital for whom we had
sufficient clinical and pathologic material to determine all the
biological markers. The distribution of clinical and pathologic data
for the entire patient population is listed in Table 1. It shows the
main clinicopathologic characteristics of the 200 node-negative
assessable patients. Eighty-three of these patients (41.5%) were
treated with radical mastectomy, 76 patients (38.0%) with modi-
fied radical mastectomy, and 41 patients (20.5%) with extended
radical mastectomy. One hundred and fifty-two of them (76.0%)
were treated by chemotherapy. Forty-one (20.5%) were treated by
mitomycin C (mitomycin C was given intravenously after mastec-
tomy, total doses ranged from 32 mg to 40 mg) and 111 patients
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(55.5%) received 5-fluorouracil or its derivatives orally. The
median follow-up duration of the patients was 10 years (range
1–20).
Pathological studies
The original histologic sections of biopsy and mastectomy speci-
mens were reviewed. Paraffin-embedded tissue samples of 4.5-
mm-thick sections stained with H&E were histopathologically
assessed. The pathologic material was reviewed without any
knowledge of the eventual clinical outcome. Conventional clinico-
pathologic features were observed and recorded, including the
clinical tumour size, histological classification, histological grade,
mitotic grade, LVI and tumour necrosis. The clinical tumour size
was determined based on the TNM classification, the histological
grade was decided based on the Bloom–Richardson grade (Bloom
and Richardson, 1957), and LVI was determined based on H&E
staining. The mitotic grade was divided into three grades based on
the number of mitoses in 10 high power fields (´400): Grade I
showed no mitoses, Grade II 1–4 mitoses, and Grade III 5 or more
mitoses. Sections of the breast tumour that were stained with H&E
were used to select the maximal area of all the cut surfaces of the
tumour that included the invasive component.
Immunocytochemical determinations
PCNA
The 4.5-mm thickness sections were dewaxed in xylene and rehy-
drated in decreasing concentrations of ethanol. The sections were
then brought to distilled water. The endogenous peroxidase
activity was blocked with 0.3% of hydrogen peroxide for 20 min.
The sections were washed in 0.05 M Tris-buffered saline, and
treated with a protein blocking agent (Japan Tanner/Lipshaw
Corporation, USA) before staining to reduce non-specific anti-
body binding. Immunostaining was performed using a mouse
monoclonal anti-human-PCNA antibody (PC10, Novocastra
Laboratories, UK) diluted at 1:100 for 24 h at 4°C. Antibody
binding was visualized by the streptavidin–biotin–immunoperoxi-
dase method (Omnitags kit; Japan Tanner/Lipshaw Corporation,
USA), followed by 0.05% 3,3¢-diaminobenzidine tetrahydrochlo-
ride development and counterstained with Meyer’s haematoxylin
and mounted. A normal human tonsil served as a positive control.
As an internal negative control, each tumour was incubated with
non-immune mouse immunoglobulin G (lgG) instead of the
primary antibody, followed by the procedure described above.
The growth fraction by PCNA staining was evaluated by counting
500 consecutive cells on one slide per tumour with a ´400 magni-
fication and an index of positive cells to total number of cells
(labelling index [LI]) was made. LI was evaluated and scored as
(–) (< mean of LI) and (+) (> mean of LI).
p53
After routine deparaffinization, the sections were pretreated by
microwaving at 500 W in 10 mM citrate buffer (pH 6) as an
antigen retrieval. The slides were placed in citrate buffer and
microwaved at full power for 5 min. After cooling by running
them through cold water, they were then slowly brought to
distilled water. The immunostaining of p53 was performed 
using a rabbit polyclonal anti-p53 antibody (CM1, Novocastra
Laboratories, UK) diluted at 1:100 for 24 h at 4°C. The remaining
steps for immunostaining were the same as described earlier.
Negative controls consisted of omission of the primary antibody.
Positive controls were sections of colon carcinomas known to
have p53 gene mutations and p53 protein accumulation.
As above, the growth fraction by p53 protein staining was eval-
uated by counting 500 consecutive cells and LI was made. LI was
evaluated and scored as (–) (< mean of LI) and (+) (> mean of LI).
Table 1 Clinicopathologic characteristics of assessable node-negative
patients
Characteristics No. of patients %
Total eligible 200
Age, years
Median 48
Range 15–82
Survival follow-up, years
Median 10
Range 1–20
Local recurrence 21 10.5
Deaths 15 7.5
Tumour size, T
T1 129 64.5
T2 56 28.0
T3 15 7.5
Menopausal status
Pre 96 48.0
Post 94 47.0
Unknown 10 5.0
Blood vessel invasion
– 166 83.0
+ 34 17.0
Lymphatic vessel invasion
– 174 87.0
+ 26 13.0
Histological grade (HG)
HG I (Well) 98 49.0
HG II (Moderate) 55 27.5
HG III (Poor) 47 23.5
Mitotic grade
(Mitotic figures per 10 HPF, ´400)
0 (Grade I) 97 48.5
1–4 (Grade II) 41 20.5
³5 (Grade III) 62 31.0
Tumour necrosis
– 111 55.5
+ 69 34.5
Histological classification
Infiltrating ductal carcinoma 180 90.0
Infiltrating lobular carcinoma 11 5.5
Medullary carcinoma 3 1.5
Mucinous carcinoma 6 3.0
PCNA
– 155 77.5
+ 38 19.0
NA 7 3.5
p53
– 155 77.5
+ 43 21.5
NA 5 2.5
c-erbB-2
– 149 74.5
+ 42 21.0
NA 9 4.5
PCNA, proliferating cell nuclear antigen; NA, not assessable.c-erbB-2
Staining for the c-erbB-2 protein was performed using a rabbit
polyclonal anti-human c-erbB-2 protein antibody (Dako,
Copenhagen, Denmark) diluted at 1:100 for 24 h at 4°C, using the
same method as for the p53 protein. Positive controls included
breast carcinomas known to exhibit high levels of protein.
Negative controls were obtained by omission of the primary anti-
body. For c-erbB-2 protein expression, membrane staining in at
least 50% of the tumour cells were considered positive according
to the criteria of Wright et al (1989).
BVI
One representative section per tumour was stained by using a
monoclonal antibody (von Willebrand factor F8/86, Dako,
Copenhagen, Denmark) with the use of a standard immunoperoxi-
dase technique and by elastica van Gieson staining described
previously (Kato et al, 1996). Briefly, formalin-fixed, paraffin-
embedded 4.5-mm sections were dewaxed in xylene, rehydrated
and immunostaining was performed using a monoclonal antibody
diluted at 1:200 at 37°C for 1 h.
BVI was determined using factor VIII-related antigen staining
and elastica van Gieson staining (Figure 1). The distinction
between lymphatic vessels and blood vessels is sometimes diffi-
cult to determine and arbitrary. While endothelial cells in the
lymphatic vessels were occasionally stained, the pattern of
staining in the lymphatic vessels was very faint, discontinuous and
inconsistent, in contrast to the intense and continuous staining
observed in the vascular endothelium. On this basis, blood vessels
could be differentiated from lymphatic vessels in our study. All
doubtful cases were considered to be negative.
BVI detected by elastica van Gieson staining was defined by
criteria similar to those of Weigand et al (1982). Blood vessels were
identified by the following characteristics. Erythrocytes in the
lumen, an endothelial cell lining, and the presence of elastic tissue
around large vessels, and ducts were identified by a zone of
acidophilic non-elastic tissue inside the elastic ring surrounding the
ducts. When BVI was difficult to distinguish from ducts invaded by
carcinoma in situ, the case was considered to be negative.
Statistical analysis
The statistical analysis of the data was performed with the
Survival Tools for Statview-J 4.5 package (Abacus Concepts,
Berkeley, CA, USA) on an Apple Power Macintosh 8100/100AV.
We examined the univariate relationships between prognostic indi-
cators and RFS and OS by fitting Kaplan–Meier survival curves
(Kaplan and Meier, 1958) to various levels of the prognostic indi-
cators. We then looked for differences among the curves using the
logrank test (Mantel, 1966). For the multivariate analysis, the Cox
proportional hazards regression model was also used (Cox, 1972).
RESULTS
Clinical outcome
Among the 200 node-negative patients, there were 21 tumour-related
local recurrences and 15 tumour-related deaths. The probability of 5-
year RFS and OS in the total patient population was 91.9% and
95.0%, respectively. However, that of 20-year RFS and OS was
88.7% and 91.3% respectively. In addition, there were seven patients
who were lost in the follow-up, and 165 patients who are alive and 13
patients who died of unrelated causes without recurrent tumours,
with follow-up examinations of up to 20 years (median 10 years).
Univariate analysis
The prognostic factors found to be significantly associated with
20-year RFS were PCNA (P < 0.0001), clinical tumour size 
(P < 0.0001), BVI (P < 0.0001), histological grade (P = 0.0007),
mitotic grade (P = 0.0016), p53 (P = 0.0043), c-erbB-2 (P =
0.0451) and LVI (P = 0.0467) (Table 2 and Figures 2A, 3A and
4A). Tumour necrosis was not associated with RFS. Moreover,
PCNA (P < 0.0001), clinical tumour size (P < 0.0001), BVI 
(P < 0.0001), histological grade (P = 0.0016), mitotic grade (P =
0.0053), LVI (P = 0.009), p53 (P = 0.0095), c-erbB-2 (P = 0.0144)
and tumour necrosis (P = 0.045) were shown to be significantly
associated with 20-year OS (Table 3 and Figures 2B, 3B and 4B).
Multivariate analysis
Multivariate analysis showed that BVI was the strongest indepen-
dent prognostic factor for RFS (c2 = 5.810; P = 0.0159; Table 4).
Patients with positive BVI were 3.48 times more likely to relapse
than those with negative BVI. PCNA was the second most predic-
tive independent prognostic factor (c2 = 5.745; P = 0.0165). The
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Figure 1 (A) Infiltrating duct carcinoma of breast, showing tumour cells within the lumen of a small blood vessel for Factor VIII-related antigen (haematoxylin
counter stain, ´400). (B) Clusters of neoplastic cells were identified within the lumen of a blood vessel and were seen growing near the external elastic
membrane stained by elastica van Gieson (elastica van Gieson staining, ´200)third most significant and independent prognostic factor was 
clinical tumour size (c2 = 5.498; P = 0.0190).
For OS, PCNA was the strongest independent predictor (c2 =
15.46; P < 0.0001). The relative risk (RR) of death was 14.15
times higher in those with positive PCNA than in those with nega-
tive PCNA. The second and third significant and independent
prognostic factors were BVI and clinical tumour size (c2 = 4.361,
P = 0.0368; c2 = 4.222, P = 0.0399 respectively). Histological
grade, mitotic grade, p53, LVI, tumour necrosis and c-erbB-2
failed to retain an independent and significant value of RFS or OS
in multivariate analysis.
Characteristics of the treatment
We examined the effect of treatment in node-negative patients for
RFS and OS. The modality of operation was not associated with
either RFS or OS. However, chemotherapy was significantly 
associated with OS but not with RFS (c2 = 4.471, P = 0.0345; 
c2 = 1.230, P = 0.2674 respectively). We fitted a model including
three prognostic factors of PCNA, BVI and chemotherapy, and
compared them by multivariate analysis. PCNA and BVI were the
significant and independent factors (c2 = 14.291, P = 0.0002; c2 =
6.565, P = 0.0104 respectively), but chemotherapy was not an
independent predictor for OS (c2 = 0.128, P = 0.7204).
Node-negative breast cancer 407
British Journal of Cancer (2000) 82(2), 404–411 © 2000 Cancer Research Campaign
Table 2 Univariate analysis of the value of prognostic factors for RFS
Variable RRa 95% Confidence c2 P
interval
Blood vessel invasion
– vs + 6.365 2.697–15.02 17.85 <0.0001
PCNA
– vs + 9.193 3.7–22.8 22.92 <0.0001
Tumour size, T
T1 vs T2 2.868 1.038–7.920 4.133 0.0421
T1 vs T3 8.99 3.016–26.80 15.53 <0.0001
Histological grade (HG)
HG I vs HG II 2.456 0.659–9.149 1.793 0.1806
HG I vs HG III 7.167 2.309–22.25 11.61 0.0007
Mitotic grade
Grade I vs Grade II 7.697 1.553–38.15 6.246 0.0125
Grade I vs Grade III 11.03 2.489–48.91 9.99 0.0016
p53
– vs + 3.489 1.481–8.219 8.173 0.0043
Lymphatic vessel invasion
– vs + 3.023 1.016–8.993 3.955 0.0467
c-erbB-2
– vs + 2.496 1.020–6.108 4.016 0.0451
Tumour necrosis
– vs + 2.307 0.978–5.441 3.649 0.0561
a Hazards ratio from Cox regression analysis. RFS, relapse-free survival;
PCNA, proliferating cell nuclear antigen; RR, relative risk.
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Figure 2 Kaplan–Meier survival curve for node-negative patients. 
(A) Relapse-free survival stratified by BVI. (B) Overall survival related to BVI
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Figure 3 Kaplan–Meier survival curve for node-negative patients. 
(A) Relapse-free survival stratified by PCNA. (B) Overall survival related 
to PCNADISCUSSION
Results of the present study indicate that BVI, PCNA and clinical
tumour size are independent prognostic indicators of RFS and OS,
and are useful in selecting high-risk node-negative breast cancer
patients who may be eligible to receive strong adjuvant therapies.
However, p53, c-erbB-2 and other conventional prognostic factors
were not associated with the outcome of the multivariate analysis.
There is adequate evidence that adjuvant chemotherapy
improves survival among patients without axillary-lymph-node
metastases (Mansour et al, 1989; Fisher et al, 1996). There have
been many reports about the poor prognostic factors indicating the
need for adjuvant treatment in node-negative patients other than
BVI, PCNA, tumour size. LVI (van de Velde et al, 1986; Lee et al,
1990; Clemente et al, 1992; Gasparini et al, 1994; Lauria et al,
1996), angiogenesis (Gasparini et al, 1994, Eppenberger et al,
1998), the mitotic count (Clayton et al, 1991), the
Bloom–Richardson grade (Davis et al, 1986, Iwaya et al, 1997),
p53 (Gasparini et al, 1994, Dittadi et al, 1997; Molina et al, 1998),
c-erbB-2 (O’Malley et al, 1996; Andrulis et al, 1998) and vascular
endothelial growth factor (Gasparini et al, 1997) have all been
reported as significant prognostic factors. However, no indicators
for the need of adjuvant treatment have yet been clearly estab-
lished. This study was undertaken to determine the absolute and
relative value of BVI using both factor VIII-related antigen and
elastica van Gieson staining, p53, PCNA, c-erbB-2 which are rela-
tively new prognostic factors, and conventional prognostic factors
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Figure 4 Kaplan–Meier survival curve for node-negative patients. 
(A) Relapse-free survival stratified by clinical tumour size. (B) Overall 
survival related to clinical tumour size
Table 3 Univariate analysis of the value of prognostic factors for OS
Variable RRa 95% Confidence c2 P
interval
Blood vessel invasion
– vs + 7.277 2.703–19.60 15.43 <0.0001
PCNA
– vs + 19.37 5.516–68.03 21.39 <0.0001
Tumour size, T
T1 vs T2 2.557 0.739–8.849 2.198 0.1382
T1 vs T3 12.59 3.832–41.33 17.43 <0.0001
Histological grade (HG)
HG I vs HG II 1.967 0.397–9.752 0.686 0.4076
HG I vs HG III 7.979 2.192–29.04 9.929 0.0016
Mitotic grade
Grade I vs Grade II 9.983 1.115–89.35 4.234 0.0396
Grade I vs Grade III 18.4 2.375–142.6 7.775 0.0053
p53
– vs + 3.661 1.373–9.761 6.731 0.0095
Lymphatic vessel invasion
– vs + 4.534 1.459–14.09 6.83 0.009
c-erbB-2
– vs + 3.698 1.297–10.544 5.984 0.0144
Tumour necrosis
– vs + 2.754 1.023–7.417 4.017 0.045
a Hazards ratio from Cox regression analysis. OS, overall survival; PCNA,
proliferating cell nuclear antigen; RR, relative risk.
Table 4 Multivariate analysis showing independent factors of RFS and OS
RFSa OSb
Variable RR 95% Confidence c2 P RR 95% Confidence c2 P
interval interval
Blood vessel invasion
– vs + 3.48 1.262–9.592 5.81 0.0159 3.211 1.074–9.598 4.361 0.0368
PCNA
– vs + 3.807 1.276–11.36 5.745 0.0165 14.15 3.776–53.00 15.46 <0.0001
Tumour size, T
T1 vs T2 2.036 0.692–5.986 1.669 0.1964 0.873 0.251–3.034 0.046 0.831
T1 vs T3 4.068 1.259–13.15 5.498 0.019 3.86 1.064–14.00 4.222 0.0399
Shown is the multivariate analysis employing Cox proportional-hazard regression of prognostic factors of RFS and OS. a In the model regarding RFS three
prognostic indicators are compared. b In the model regarding OS three prognostic indicators are compared. RFS, relapse-free survival; OS, overall survival;
PCNA, proliferating cell nuclear antigen; RR, relative risk.in predicting RFS and OS rates with long-term follow-up in
Japanese patients with node-negative breast cancer.
Weigand et al (1982) and others (Sampat et al, 1978) reported
that the presence of tumour cell (TC) emboli in blood vessels
correlated significantly with a high rate of recurrence. However, it
was more difficult to identify invasion of small vessels and capil-
laries in breast cancer in routine H&E-stained tissue sections than
in gastric cancer or in colorectal cancer. Therefore we used factor
VIII-related antigen staining and were thus able to successfully
detect BVI. Factor VIII-related antigen has been well established
as a marker for vascular endothelial cells (Bettelheim et al, 1984;
Martin et al, 1987), and is consistently found in normal endothelial
cells in blood vessels; while endothelial cells in lymphatic vessels
were occasionally stained, the pattern of staining was very faint
and discontinuous. Several studies (Bettelheim et al, 1984; Martin
et al, 1987) have examined the use of immunohistochemical tech-
niques to identify blood vessels and lymphatic vessels; but others
(Saigo et al, 1987) have reported that immunohistochemical stains
may be of assistance in occasional cases and that examination of
H&E stains is the most reliable method.
Some clinical studies suggested that to use an antibody to CD31
may be superior to using factor VIII-related antigen (Horak et al,
1992; Fox et al, 1994); however, the other study reported that this
greater sensitivity of anti-CD31 of vascular endothelium did not
yield results more discriminating for predicting survival outcome
than results produced with factor VIII-related antigen (Gasparini et
al, 1994). It may lack accuracy, however, many stromal vessels can
be stained very well and be counted by factor VIII-related antigen
staining as we previously reported and there was a strong relation-
ship between BVI and angiogenesis (Kato et al, 1999). In this
study, incidence of BVI detected by factor VIII-related antigen
staining was about twice as high as that of BVI detected by elastica
van Gieson staining, so factor VIII-related antigen is a practical
and effective way of identifying endothelial cells lining arteries,
veins and capillaries.
In our experience, it was difficult to distinguish among BVI,
pseudoemboli resulting from shrinkage where cancer cells peeled
off from the ducts by poor fixing, and lymphatic invasion only by
H&E staining, while it was relatively easy to detect BVI using
factor VIII-related antigen staining. Immunohistochemical
staining with factor VIII-related antigen staining facilitated the
identification of blood vessels and lymphatic vessels and also
helped to eliminate pseudoemboli resulting from shrinkage.
Detection of the blood vessels infiltrated by tumour cells and those
in which tumour cells were floating was easy, however, detection
of the blood vessels filled with TC emboli by this staining alone
was difficult as we have previously published (Kato et al, 1996).
There was possibility of overlooking the blood vessels filled with
TC emboli using factor VIII-related antigen staining alone.
Therefore we also used elastica van Gieson staining to detect the
blood vessels with TC emboli. To actually detect blood vessels
filled with TC emboli and invaded by cancer cells by factor VIII-
related antigen staining alone was impossible because the endothe-
lial cells could not be stained well. Elastica van Gieson staining
proved to be a useful method for such blood vessels filled with TC
emboli. However, it was sometimes difficult to distinguish BVI
from ductal carcinoma in situ covered with elastic fibre. In such
cases, it was considered negative. We used factor VIII-related
antigen staining to detect the small blood vessels which did not
have elastic fibre and also used elastica van Gieson staining to
detect the large blood vessels filled with TC emboli, and thereby
blood vessels detected by the former staining method were differ-
entiated from those detected by the latter. We therefore consider it
necessary to use both staining methods when we detect BVI.
In this study BVI in the 200 node-negative patients who we
observed was seen in 34 cases (17.0%). This rate of BVI is higher
than that of another study by Lee et al (1990). When they exam-
ined the prognostic value of PLBI, the frequencies of BVI and LVI
were 7% and 21% respectively. They detected BVI using factor
VIII-related antigen staining and ABH isoantigen. As we could
detect the larger blood vessels filled with TC emboli by elastica
van Gieson staining, our frequencies of BVI might be higher than
theirs. However, when PLBI was separated into LVI and BVI indi-
vidually, the prognostic importance of TC emboli was retained in
both groups. Our results are similar to theirs regarding survival.
BVI is thus suggested to be an adverse prognostic factor among
node-negative patients.
A relationship between tumour size and prognosis has been
reported in several studies of node-negative patients. In some large
series, it was found that increasing tumour size was related to the
likelihood of recurrence (Rosen et al, 1989; Clayton et al, 1991;
Lampe et al, 1998). But in several other studies, tumour size was
not found to be significant (Sears et al, 1982; van de Velde et al,
1986). In the present study, clinical tumour size was an effective
factor. The T3 tumour had a particularly poor prognosis.
Cell proliferation is an important prognostic indicator in breast
cancer (McGuire et al, 1990). The proliferative index of breast
cancer has been judged by immunohistochemistry with mono-
clonal antibodies to other proliferation markers such as PCNA and
Ki-67 (Isola et al, 1990; Bianchi et al, 1993; Sitonen et al, 1993;
Railo et al, 1997; Clahsen et al, 1998). They have been shown to
have some prognostic value in breast cancer. In this study, PCNA
was shown to be significantly associated with RFS and OS. PCNA
was the strongest independent factor for OS. The relative risk of
death was 14.2 times higher in patients with positive PCNA than in
those with negative PCNA proving it a strong prognostic factor
among node-negative patients.
There are contradictory findings concerning the correlation of c-
erbB-2 expression and survival of patients in node-negative breast
cancer patients; some clinical trials confirmed this association
(O’Malley et al, 1996; Andrulis et al, 1998), whereas others found
no correlation (Harbeck et al, 1998; Lampe et al, 1998). In this
study, c-erbB-2 expression was a significant prognostic factor in
univariate analysis, however, not associated with the outcome of
the multivariate analysis. These discrepancies may be due to some
technical reasons, the small number of cases studied, the different
follow-up period, the different races and different characteristics
of the patients.
The association of p53 protein accumulation and prognosis in
node-negative breast cancer patients has been alternately demon-
strated. Some clinical studies found correlation between p53
protein accumulation and prognosis (Gasparini et al, 1994; Dittadi
et al, 1997; Molina et al, 1998); however, other authors did not find
any correlation at all (Harbeck et al, 1998; Lampe et al, 1998). The
prognostic value remains controversial. In our sample, p53 has a
prognostic role in univariate analysis and was a borderline signifi-
cant prognostic factor in multivariate analysis for 20-year RFS
(RR = 2.506, 95% confidence interval = 0.95–6.606, P = 0.0633).
The significance of p53 as a prognostic role in breast cancer
should be addressed with methods that investigate the correlation
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studies.
Seventy-six per cent of all node-negative breast cancer patients
were treated by mitomycin C or 5-fluorouracil or its derivatives in
this study. The percentage of patients who received chemotherapy
is quite higher than that in recent studies of other researchers
(Barbareschi et al, 1996). We compared the prognosis of the node-
negative patients who underwent chemotherapy with those who
did not. Our study confirms that this kind of weak regimen of
chemotherapy appears somewhat effective in node-negative
patients for OS by univeriate analysis but not for RFS. When we
compared PCNA, BVI and chemotherapy by multivariate analysis,
such a regimen was not an independent factor for OS, so it was not
relevant as a significant prognostic factor. In the same way, there
was no effectiveness of modality of operation for OS nor RFS.
The results of our study shows that the probability of 5-year
RFS and OS in the total patient population was better than that of
other researchers (Tandon et al, 1990; Gasparini et al, 1994). This
may be due to various factors. First, there is different epidemi-
ology, especially a higher proportion of Japanese patients in the
premenopausal age group than the Caucasian women in
Haagensen’s book, and the distribution by age at the time of the
operation in Japanese patients was different from that in those
Caucasian patients (Haagensen, 1986). Second, the prognosis of
Japanese patients is better than that of Caucasian women due to
biological behaviour (Wynder et al, 1963; Stemmermann et al,
1985). Finally, there were more patients in this study treated by
chemotherapy than those in other studies (Barbareschi et al, 1996).
We acknowledge that the number of patients in some of the
subgroups in our analysis is not as large as would be desirable and
that a larger number of patients will be required to better assess
these relationships with greater certainty, but we concluded that
BVI, PCNA and clinical tumour size are prognostic factors of RFS
and OS in Japanese patients with node-negative breast cancer.
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